Splice Bio announces research funding by Cystic Fibrosis Foundation to develop novel AAV vectors

BARCELONA, December 10, 2020 – Splice Bio, a biotech company based on technology developed in the Muir Lab at Princeton University, announced today a research agreement with the Cystic Fibrosis Foundation to develop novel adeno-associated viruses (AAVs) aimed at treating people suffering from cystic fibrosis (CF). The Company will receive up to $343,000 in research funding to advance its proprietary 3 rd -generation intein platform and develop novel AAVs better suited to target specific cells in the lungs of people with CF. “We are excited to work together with the Cystic Fibrosis Foundation and look forward to advancing novel gene therapies that can contribute to the development of a cure for cystic fibrosis”, said Miquel Vila-Perelló, co-founder and CEO of Splice Bio.